BMS revises hepatitis B therapy warning label

The FDA reports that Bristol-Myers Squibb has revised hepatitis B therapy Baraclude's boxed warning labeling to caution against its use in HIV/hepatitis B virus co-infected patients who are not also receiving highly active antiretroviral therapy due to the potential for developing HIV resistance.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.